BBV154

BBV154
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Routes of; administration	Intranasal
ATC code	None;

BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,^[1]^[2] American company Precision Virologics^[3]^[4] and the Washington University School of Medicine in St Louis, Missouri, United States.^[5]^[6]

Clinical trials[]

Phase I trials[]

On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial.^[7]

Phase II and III trials[]

On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers.^[8]

References[]

^ Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov
^ "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
^ "St. Louis-based Precision Virologics and India's Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology". www.biostl.org. Retrieved 29 August 2021.
^ Hassan, AO; Kafai, NM; Dmitriev, IP; Fox, JM; Smith, BK; Harvey, IB; Chen, RE; Winkler, ES; Wessel, AW; Case, JB; Kashentseva, E; McCune, BT; Bailey, AL; Zhao, H; VanBlargan, LA; Dai, YN; Ma, M; Adams, LJ; Shrihari, S; Danis, JE; Gralinski, LE; Hou, YJ; Schäfer, A; Kim, AS; Keeler, SP; Weiskopf, D; Baric, RS; Holtzman, MJ; Fremont, DH; Curiel, DT; Diamond, MS (1 October 2020). "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2". Cell. 183 (1): 169–184.e13. doi:10.1016/j.cell.2020.08.026. PMC 7437481. PMID 32931734.
^ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
^ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
^ Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.
^ Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.

External links[]

Scholia has a profile for BBV154 (Q106309712).

Bharat Biotech's Intranasal Vaccine for COVID-19: Everything we know so far about BBV154 firstpost.com

This article about COVID-19 vaccines is a stub. You can help Wikipedia by .

This article about vaccines or vaccination is a stub. You can help Wikipedia by .

[NCT04751682-1] Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov

[2] "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.

[3] "St. Louis-based Precision Virologics and India's Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology". www.biostl.org. Retrieved 29 August 2021.

[4] Hassan, AO; Kafai, NM; Dmitriev, IP; Fox, JM; Smith, BK; Harvey, IB; Chen, RE; Winkler, ES; Wessel, AW; Case, JB; Kashentseva, E; McCune, BT; Bailey, AL; Zhao, H; VanBlargan, LA; Dai, YN; Ma, M; Adams, LJ; Shrihari, S; Danis, JE; Gralinski, LE; Hou, YJ; Schäfer, A; Kim, AS; Keeler, SP; Weiskopf, D; Baric, RS; Holtzman, MJ; Fremont, DH; Curiel, DT; Diamond, MS (1 October 2020). "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2". Cell. 183 (1): 169–184.e13. doi:10.1016/j.cell.2020.08.026. PMC 7437481. PMID 32931734.

[5] "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.

[6] "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.

[7] Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.

[8] Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments China US Fake treatments Protests US Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths Zero-COVID National responses Africa China European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Vaccine candidates CoronaVac Covaxin Convidecia Janssen Moderna Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Canadian meat US meat Food security Journalism Music Performing arts Retail Shipping Sports Ireland Philippines Television US programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Ireland Death rates by country Disability Domestic violence Emergency evacuations Education Female Ghana Ireland UK US Environment Hospitals Language LGBT community Long-term care Mental health Symptoms Migration Military Notable deaths South Africa Other health issues Politics Ireland Malaysia Russia Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Society Ireland Malaysia New Zealand Russia UK US Strikes Suicides Telehealth Xenophobia and racism
COVID-19 portal
v t